| Dr Jay Patrick Nichols, MD | |
|
1670 Makaloa St # 204-351, Honolulu, HI 96814-3232 | |
| (808) 762-1135 | |
| Not Available |
| Full Name | Dr Jay Patrick Nichols |
|---|---|
| Gender | Male |
| Speciality | |
| Experience | Years |
| Location | 1670 Makaloa St # 204-351, Honolulu, Hawaii |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144562588 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | MD-21964 (Hawaii) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jay Patrick Nichols, MD 1670 Makaloa St # 204-351, Honolulu, HI 96814-3232 Ph: (808) 762-1135 | Dr Jay Patrick Nichols, MD 1670 Makaloa St # 204-351, Honolulu, HI 96814-3232 Ph: (808) 762-1135 |
News Archive
The American Society of Clinical Oncology (ASCO) today issued a clinical practice guideline on human papillomavirus (HPV) vaccination for the prevention of cervical cancer.
We all love our sugar, especially during the holidays. Cookies, cake, and candy are simply irresistible. While sugar cravings are common, the physiological mechanisms that trigger our "sweet tooth" are not well defined.
Dr. Felix-Martin Werner, working at the Euro Academy Pößneck in Germany and Prof. Rafael Coveñas, working at the Institute of Neurosciences of Castilla and León, Salamanca in Spain, have been working on neurological and psychiatric disease for over ten years.
AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) announced overall survival (OS) for tivozanib, an investigational agent, from the Phase 3 TIVO-1 (TIvozanib Versus sOrafenib in 1st line advanced RCC) study in patients with advanced renal cell carcinoma (RCC). The final OS analysis, as specified by the protocol, shows a median OS of 28.8 months (95% confidence interval [CI]: 22.5–NA) for tivozanib versus a median OS of 29.3 months (95% CI: 29.3–NA) for the comparator arm, sorafenib.
Authors of a research letter in this week's issue of THE LANCET highlight how the use of drug-eluting stents (DES) may carry a risk of subsequent thrombosis if stenting is accompanied by a withdrawal of antiplatelet therapy.
› Verified 4 days ago
Sohee Ki, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1356 Lusitana St Fl 4, Honolulu, HI 96813 Phone: 808-586-2903 | |
Dr. Robert C. Pedersen, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 2828 Paa St, Honolulu, HI 96819 Phone: 808-432-5777 | |
Dr. David H.f. Tom, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1100 Ward Ave, Suite 840, Honolulu, HI 96814 Phone: 808-522-4521 Fax: 808-522-3526 | |
Dr. Beau K. Nakamoto, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 888 S King St, Honolulu, HI 96813 Phone: 808-522-4000 Fax: 808-522-4437 | |
Dr. Christina S Hines, MD., PH.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 459 Patterson Rd, Honolulu, HI 96819 Phone: 808-433-0320 | |
Daniel A. Alicata, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1356 Lusitana St, 4th Floor, Honolulu, HI 96813 Phone: 808-586-2900 | |
Angela Hu, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1356 Lusitana St Fl 4, Honolulu, HI 96813 Phone: 808-586-2903 |